Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19

October 28, 2020 updated by: Ernesto Cesar Pinto Leal Junior, University of Nove de Julho

Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?

Coronavirus disease 2019 (COVID-19) is a disease caused by a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). The most characteristic symptom of patients with COVID-19 is respiratory distress, leading to inability to sustain spontaneous breathing. In addition, patients with COVID-19 have dyspnea and respiratory muscle fatigue. Therefore, it is necessary to use strategies that minimize the impact of COVID-19 on the respiratory muscles, accelerating the ventilatory weaning process and optimizing the functional capacity of the involved muscles.

Over the past years, evidence has shown the effectivity of photobiomodulation therapy (PBMT) combined with static magnetic field (sMF) (PBMT/sMF) in delaying muscle fatigue, decrease in markers of inflammatory damage and oxidative stress of skeletal muscle. These effects result in an improvement in the functional capacity of the irradiated muscles by PBMT/sMF. However, do date, there is a lack of evidence regarding the effects of PBMT/sMF on the respiratory muscles.

Therefore, the irradiation of PBMT/sMF may result in improvement in the functional capacity of respiratory muscles in patients with COVID-19, accelerating the ventilatory weaning process of the patients intubated due to respiratory failure. In addition, the irradiation of PBMT/sMF may induce the increase of anti-inflammatory mediators' activity in patients with COVID-19.

Thus, the aim of this project is to investigate the effects of PBMT/sMF on respiratory muscles of patients admitted to the Intensive Care Unit (ICU) with COVID-19 using invasive mechanical ventilation.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To achieve the proposed objectives it will be performed a randomized, triple-blind, placebo-controlled trial, with patients admitted to the adult ICU with COVID-19 using invasive mechanical ventilation due to respiratory failure. The patients will be randomly allocated to two treatment groups: 1. Active PBMT/sMF (MR5™ ACTIV PRO LaserShower) or Placebo PBMT/sMF (MR5™ ACTIV PRO LaserShower). The patients will be treated by a blinded therapist, and the patients will be blinded to the treatment received.

Since there are no studies in this field, initially it will be randomized 30 patients (15 patients per group) to determine the final sample size for this study.

The patients randomly allocated to the two groups will be subjected to treatment once a day, during the ICU stay, until discharge or death.

All data will be collected by a blinded assessor. The investigators will analyze:

  1. Number of days hospitalized in the ICU until discharge or death.
  2. Survival rate: rate of how many people survived and were discharged and how many died.
  3. Muscular function of the diaphragm: the first assessment will be performed within 24 hours after the patient's intubation, the second 10 days after the first, and the third at the pre-discharge from the ICU.
  4. Blood tests: baseline (admission to the ICU), 10 days after the admission, and endpoint (discharge or death).
  5. Mechanical ventilation control parameters: baseline (admission to the ICU), 10 days after the admission, and endpoint (discharge or death).
  6. Arterial Blood Gas Analysis: baseline (admission to the ICU), 10 days after the admission, and endpoint (discharge or death).

The data regarding the blood tests and arterial blood gas analysis will be collected directly from electronic medical record of each patients, since it is a daily hospital routine to perform these blood tests. The data will be collected by two assessors blinded to the treatment applied. The mechanical ventilation control parameters will be collected directly in the mechanical ventilator.

Statistical analysis: All the data will be analyzed by a blinded researcher not involved in data collection. The findings will be tested for their normality using the Kolmogorov-Smirnov test. Parametric data will be expressed as mean and standard deviation and non-parametric data as median and respective upper and lower limits, data can be also expressed as frequency (%). Parametric data will be analysed by two-way repeated measures analysis of variance (time vs experimental group) with post hoc Bonferroni correction. Non-parametric data will be analysed using the Friedman test and, secondarily, the Wilcoxon signed-rank test. The association between categorical variables will be analyzed using the Chi-square test or Fisher's exact test. The significance level will be set at p<0.05.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • RS
      • Bento Gonçalves, RS, Brazil, 95700-068
        • Hospital Tacchini

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients admitted to the adult Intensive Care Unit with Covid-19 infection;
  • Need for orotracheal intubation;
  • Invasive mechanical ventilation due to respiratory failure.

Exclusion Criteria:

  • Suspected patients who had a negative result of the diagnostic examination for COVID-19 infection;
  • Patients positioned in pronation for more than 24 hours;
  • Cancer patients;
  • Pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PBMT/sMF

Active PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with PBMT/sMF.

PBMT/sMF will be applied using MR5™ ACTIV PRO LaserShower, manufactured by Multi Radiance Medical (Solon, OH, USA). This device has 4 diodes of 905 nm (1.25 mW each diode, 0.32 cm2 each), 8 diodes of 633 nm (25 mW each diode, 0.85 cm2 - each), and 8 diodes of 850 nm (40 mW each diode, 0.56 cm2 - each). The static magnetic field is 110 mT.
Device: Active PBMT/sMF
The PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used in the lower thorax will be 31.50 J per site, a total of 6 sites will be irradiated, totalizing a dose of 189J. In addition, the dose used in the neck area (bilaterally) will be 31.50J per site, a total of 1 site (bilaterally) will be irradiated, totalizing a dose of 31.50J (bilaterally). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.
Placebo Comparator: Placebo PBMT/sMF

Placebo PBMT/sMF will be applied once a day, during the ICU stay, until discharge or death. The patients will receive standard physical therapy care associated with placebo PBMT/sMF.

The placebo PBMT will be applied using MR5™ ACTIV PRO LaserShower Laser Therapy System, manufactured by Multi Radiance Medical (Solon, OH, USA). The ACTIV PRO emits 905nm, and 850nm via an electric diode energy source with outputs to 0%. The static magnetic field will be also turned off. The 660nm light via an electric diode energy source with outputs to >1% to appear like the active comparator.
Device: Placebo PBMT/sMF
The placebo PBMT/sMF will be irradiated in the lower thorax and neck areas, with the patients in supine position. PBMT/sMF application time will be 60 seconds per site. The dose used for applications during the treatment will be 0 Joules (J) per site. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). PBMT/sMF will be applied using the direct contact method with light pressure on the skin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time until discharge
Time Frame: From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 20 days.
Number of days hospitalized in the ICU until discharge or death.
From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 20 days.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survival rate
Time Frame: From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 20 days.
Rate of how many people survived and were discharged and how many died.
From date of randomization until the date of discharge or date of death from any cause, whichever came first, assessed up to 20 days.
Diaphragm muscle function
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Diaphragm thickness will be measured by ultrasound.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Platelet count
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Platelet count will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Leukogram
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Leukogram will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Erythrogram
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Erythrogram will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
C-reactive protein
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
C-reactive protein will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
D-dimer
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
D-dimer will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Immunoglobulin G
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Immunoglobulin G will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Immunoglobulin M
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Immunoglobulin M will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Levels of positive end-expiratory pressure (PEEP)
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
The levels of PEEP will be measured using a mechanical ventilator.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Fraction of inspired oxygen (FiO2)
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
The levels of FiO2 will be measured using a mechanical ventilator.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Arterial partial pressure of oxygen (PO2)
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
PO2 will be measured by arterial blood gas analysis.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Arterial partial pressure of oxygen (PO2)/Fraction of inspired oxygen (FiO2) ratio
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
PO2/FiO2 ratio will be measured by arterial blood gas analysis.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Levels of tumor necrosis factor-α (TNF-α)
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Levels of TNF-α will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Levels of vitamin D
Time Frame: 10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.
Levels of vitamin D will be measured by blood test.
10 days after randomization and in the last test before discharge or death from any cause, whichever came first, assessed up to 20 days.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Nove de Julho

Collaborators

Hospital Tacchini/RS

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 18, 2020

Primary Completion (Actual)

September 17, 2020

Study Completion (Actual)

September 17, 2020

Study Registration Dates

First Submitted

May 8, 2020

First Submitted That Met QC Criteria

May 11, 2020

First Posted (Actual)

May 13, 2020

Study Record Updates

Last Update Posted (Actual)

October 29, 2020

Last Update Submitted That Met QC Criteria

October 28, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 3.985.226

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on Active PBMT/sMF

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe